Capsugel Enters Agreement with Chiasma for Scale-Up Manufacture of Oral Octreotide Acetate Capsugel today announced an agreement with Chiasma, Inc., wherein Capsugel’s Dosage Form Solutions (DFS) business unit is scaling up manufacturing for the only investigational oral form of octreotide in clinical development. (PRWeb April 28, 2014) Read the full story at http://www.prweb.com/releases/2014/04/prweb11800452.htm
April 28, 2014 - PRWeb